Cargando…

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes

BACKGROUND: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 increases the levels of the incretin hormones glucagon-like peptide and glucose-dependent insulinotropic polypeptide by preventing their degradation. OB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoimark, Lene, Laursen, Torben, Rungby, Jørgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430084/ https://www.ncbi.nlm.nih.gov/pubmed/22952411 http://dx.doi.org/10.2147/DMSO.S16288

Ejemplares similares

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
por: Baruah, Manash P., et al.
Publicado: (2016)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial
por: Ji, Linong, et al.
Publicado: (2015)

Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment
por: Guedes, Erika Paniago, et al.
Publicado: (2013)

Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
por: Haak, Thomas
Publicado: (2015)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
por: Kapitza, C, et al.
Publicado: (2013)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley, Richard E
Publicado: (2014)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
por: Falk, Jeremy A, et al.
Publicado: (2010)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
por: von Websky, Karoline, et al.
Publicado: (2013)

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial
por: Ma, Ronald CW, et al.
Publicado: (2017)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
por: Philis-Tsimikas, Athena, et al.
Publicado: (2013)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
por: Wang, Bruce, et al.
Publicado: (2015)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
por: Groop, P-H, et al.
Publicado: (2014)

New developments in the treatment of rosacea – role of once-daily ivermectin cream
por: Cardwell, Leah A, et al.
Publicado: (2016)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

Potential benefit of dolutegravir once daily: efficacy and safety
por: Fantauzzi, Alessandra, et al.
Publicado: (2013)

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
por: Buse, John B., et al.
Publicado: (2010)

Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1
por: Takase, Yuuki, et al.
Publicado: (2021)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
por: Retlich, Silke, et al.
Publicado: (2015)

Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice
por: Zhang, Yanqing, et al.
Publicado: (2017)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

A randomized trial of once daily versus twice daily dosing of oral iron in CKD
por: Sood, Vivek, et al.
Publicado: (2023)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Clinical utility and tolerability of linagliptin in diabetic patients
por: Maxwell, Lauralee Gordon, et al.
Publicado: (2013)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats
por: Šutalo, S., et al.
Publicado: (2015)

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott, David
Publicado: (2013)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lg98bs4pn04q07cgrbihn42bop